Differences in antithrombin III activities by administration method in critical patients with disseminated intravascular coagulation: A pharmacokinetic study

Shock

Volumn 28, Issue 2, 2007, Pages 141-147

  Aibiki, Mayuki ^a   Fukuoka, Noriyasu ^b   Nishiyama, Takashi ^a   Maekawa, Soichi ^a   Shirakawa, Yoichi ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KAGAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Administration method; Antithrombin; Bleeding tendency; Disseminated intravascular coagulation; Pharmacokinetics; Vascular permeability

Indexed keywords

ANTITHROMBIN III;

ADULT; AGED; ANTITHROMBIN DEFICIENCY; ARTICLE; BLEEDING TENDENCY; BLOOD VESSEL PERMEABILITY; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPARTMENT MODEL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; JAPAN; MALE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTITHROMBIN III; CRITICAL CARE; DISSEMINATED INTRAVASCULAR COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 34547659131     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/shk.0b013e31803422c4     Document Type: Article

References (17)

1. Ilias W, List W, Decruyenaere J, Lignian H, Knaub S, Schindel F, Keinecke HO, Heinrichs H, Thijs LG: Antithrombin III in patients with severe sepsis: a pharmacokinetic study. Intensive Care Med 26:704-715, 2000.
2. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, et al.: KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869-1878, 2001.
3. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM: KyberSept Investigators. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 34:285-292, 2006.
4. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM: KyberSept Investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 4:90-97, 2006.
5. Nakagawa M, Tsuji H, Matsumura H, Kakishita E, Matsuo T, Sakuragawa N, Takahashi K, Oh H, Miyayama T: Changes in post-administered antithrombin III activity in congenital AT III deficiency patients. Sinryo to Sinyaku 22:2139-2146, 1985. [in Japanese].
6. Tengborn L, Frohm B, Nilsson LE, Nilsson IM: Antithrombin III concentrate: its catabolism in health and in antithrombin III deficiency. Scand J Clin Lab Invest 41:469-477, 1981.
7. Collen D, Schetz J, de Cock F, Holmer E, Verstraete M: Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration. Eur J Clin Invest 7:27-35, 1977.
8. Sakata Y, Yoshida N, Matsuda M, Aoki N: Treatment of DIC with antithrombin III concentrates. In Abe T, Yamanaka M (eds.): Disseminated Intravascular Coagulation. Tokyo, Japan: University of Tokyo Press, pp 307-316, 1983.
9. Fukuoka N, Aibiki M, Kikuchi S, Umakoshi K, Maekawa S, Nishiyama T, Shirakawa Y: Albumin administration maintains post-administered anti-thrombin III trough activity in critically ill patients. Shock 23(suppl):87-88, 2005.
10. Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H: Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol 49:265-275, 1983.
11. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001, SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250-1256, 2003.
12. Aibiki M, Fukuoka N, Umakoshi K, Ohtsubo S, Kikuchi S: Serum albumin levels anticipate antithrombin III (AT) activities before and after AT agent in critical patients with disseminated intravascular coagulation. Shock 27:139-144, 2007.
13. Yamaoka K, Tanigawara Y, Nakagawa T: A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879-885, 1981.
14. Groner A, Nowak T, Romisch J: Purity, activity, and virus safety of a pasteurized antithrombin concentrate. Semin Thromb Hemost 28(suppl 1): 79-85, 2002.
15. Asakura H, Sano Y, Omote M, Yoshida T, Ontachi Y, Mizutani T, Kaneda M, Yamazaki M, Morishita E, Takami A, et al.: Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. Eur J Haematol 67:170-175, 2001.
16. Blauhut B, Kramar H, Vinazzer H, Bergmann H: Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 39:81-89, 1985.
17. Kountchev J, Bijuklic K, Bellmann R, Wiedermann CJ, Joannidis M: Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis. Crit Care 9:R596-R600, 2005.